Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 36.2% from a year ago

Cash & equivalents stood at $156.16M at the end of Q1 FY2026, up 36.2% from a year earlier and down 7.0% from the prior quarter. Over 3 fiscal years it compounded at +10.4% a year.

Context

  • Cash & equivalents amounted to 33.8% of total assets at the end of Q1 FY2026, down 1.6 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +36.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$156.16M-7.0% QoQ
Last fiscal yearDec 2025
$167.85M+16.0% YoY
Year agoMar 2025
$114.63M+36.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.2%——
1 year+16.0%——
3-year CAGR+10.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
167.85M USD
Year-over-year change
+16.0%
4-year CAGR
-5.3%

Cash & Equivalents vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +36.2% is the 4th highest of 10, against a peer median of +5.7%.
  • Cash & equivalents amounts to 33.8% of total assets for ESPR, versus a peer median of 13.6%.
ESPR Competitors
Cash & Equivalents for ESPR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SNDLSNDL Inc.Mar 2026CA$233.36M CAD+5.7%-0.8%17.8%
EBSEmergent BioSolutions Inc.Mar 2026$160.3M USD+7.5%-31.6%12.1%
ESPREsperion Therapeutics, Inc.Mar 2026$156.16M USD+36.2%+10.4%33.8%
SIGASIGA Technologies, Inc.Mar 2026$145.56M USD-10.3%+16.2%66.3%
OFIXOrthofix Medical Inc.Mar 2026$120.28M USD+107.5%+17.4%13.6%
AQSTAquestive Therapeutics, Inc.Mar 2026$110.73M USD+61.3%+64.4%78.5%
OLMAOlema Pharmaceuticals, Inc.Mar 2026$52.55M USD+3.8%+26.8%9.9%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$40.1M USD+702.2%-29.7%15.8%
RGNXREGENXBIO Inc.Mar 2026$15.23M USD-88.3%-29.2%4.5%
ABSIAbsci CorporationMar 2026$8.63M USD-81.6%-30.6%4.4%
Peer median (excluding ESPR) —+5.7%-0.8%13.6%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents208.89M124.78M82.25M144.76M167.85M
Short-term Investments50.44M42.09M000
Net Receivables22.93M33.73M48.49M80.14M140.19M
Inventory34.39M35.2M65.62M94.49M105.12M
Other Current Assets11.17M9.87M4.51M18.02M4.5M
Total Current Assets328.97M246.68M201.07M338M462.57M
Property, Plant & Equipment (Net)2.56M1.2M4.68M5.77M3.26M
Goodwill00000
Intangible Assets56K56K56K56K56K
Long-term Investments00000
Tax Assets0000417.85M
Other Non-current Assets50M000(123.13M)
Total Non-current Assets52.62M1.26M4.73M5.82M298.03M
Total Assets381.59M247.94M205.8M343.82M465.89M
Account Payables17.56M23.04M31.72M51.65M65.07M
Short-term Debt12.69M25.14M34.83M102.16M89.7M
Tax Payables00000
Deferred Revenue5.68M3.51M25.4M8.52M34.48M
Other Current Liabilities8.81M9.05M49.24M12.74M9.84M
Total Current Liabilities73.35M92.31M156.22M246.23M300.81M
Long-term Debt258.28M259.9M501.55M483.74M457.65M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)634K0000
Other Non-current Liabilities245.74M218.85M239.95M246.02M8.74M
Total Non-current Liabilities505.18M479.41M504.57M486.31M467.04M
Total Liabilities578.53M571.72M660.79M732.54M767.85M
Common Stock61K75K118K196K245K
Retained Earnings(1.11B)(1.34B)(1.55B)(1.6B)(1.62B)
Accumulated OCI(31K)(2K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(196.94M)(323.78M)(454.99M)(388.72M)(301.97M)
Total Debt260.2M260.95M540.95M591.21M548M
Net Debt51.3M136.17M458.7M446.45M380.15M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.